Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Unknown 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 9Endometrial Neoplasms 4Carcinoma, Renal Cell 4Neuroendocrine Tumors 3Tuberous Sclerosis 2Recurrence 2Neoplasm Metastasis 2Kidney Neoplasms 2Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Diseases 1Solid Tumor 1Seizures 1Sarcoma 1Primary Non-metastatic Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Endocrine Neoplasia Type 1 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Hyperplasia 1Clear-cell metastatic renal cell carcinoma 1Breast Neoplasms, Male 1Angiomyolipoma 1Advanced Solid Tumors 1Advanced Cancer 1

Interventions

Azacitidine 38Cytarabine 37venetoclax 34fludarabine 28Cyclophosphamide 21Daunorubicin 18fludarabine phosphate 17Decitabine 16Specimen Handling 15Tacrolimus 14Busulfan 13Injections 12Biopsy 12Melphalan 11Granulocyte Colony-Stimulating Factor 11CPX-351 11Mycophenolic Acid 10Idarubicin 10Stem Cell Transplantation 9Whole-Body Irradiation 8Etoposide 8decitabine and cedazuridine drug combination 7Thiotepa 7Mitoxantrone 7enasidenib 6Peripheral Blood Stem Cell Transplantation 6Methotrexate 6ivosidenib 5gilteritinib 5Gemtuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myeloid, Acute × Everolimus × Clear all
NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
29 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡